Dysmenorrhea Therapeutic Apparatus

Abstract

A dysmenorrhea therapeutic apparatus, comprising a housing (13), a vaporization assembly (1), and a hose assembly (2). The vaporization assembly (1) includes a housing (13), a high-pressure cylinder assembly (11) disposed within the housing (13), and a heating element (113). The technical key points are as follows: The high-pressure cylinder assembly (11) includes a first-stage high-pressure chamber and a second-stage high-pressure chamber that are vertically arranged and connected through a first-stage solenoid valve. The heating element (113) is disposed at the bottom of the first-stage high-pressure chamber. A buffer cylinder (12) is provided on the side of the high-pressure cylinder assembly (11). The buffer cylinder (12) is connected to the second-stage high-pressure chamber through a second-stage solenoid valve; the buffer cylinder (12) is connected to the hose assembly (2) through a third-stage solenoid valve (124). It has the advantages of simple and compact structure, convenient use, and easy operation, etc.

Description

Technical Field

[0001] The present invention relates to the field of medical devices, in particular to a dysmenorrhea treatment device, whose IPC main classification number mainly relates to A61H39 / 00. Background Art

[0002] Dysmenorrhea is one of the most common gynecological symptoms, which refers to pain and distension in the lower abdomen before, during or after menstruation, accompanied by backache or other discomfort, and the symptoms seriously affect the quality of life. Dysmenorrhea is divided into primary dysmenorrhea and secondary dysmenorrhea. Primary dysmenorrhea refers to dysmenorrhea without organic lesions of the reproductive organs; secondary dysmenorrhea refers to dysmenorrhea caused by organic diseases of the pelvic cavity, such as endometriosis and adenomyosis. Traditional Chinese medicine believes that the pathogenesis of dysmenorrhea is mainly due to the influence of pathogenic factors, which leads to blood stasis in the Chong and Ren meridians or cold stagnation in the meridians, which makes the flow of qi and blood in the uterus obstructed, resulting in "pain due to obstruction": or the Chong and Ren meridians and the uterus are not nourished, and the pain is caused by lack of nourishment. The disease is located in the Chong and Ren meridians and the uterus, and the changes are in the qi and blood, which manifests as pain. The reason why it occurs with the menstrual cycle is related to the changes in the qi and blood of the Chong and Ren meridians during the menstrual period.

[0003] Dysmenorrhea refers to the pain in the lower abdomen or waist and general discomfort that women experience during and before and after menstruation. Severe dysmenorrhea may be accompanied by nausea and vomiting, cold hands and feet, and even fainting, which seriously affects work and life. Western medicine mainly treats it through painkillers, hormone drugs and surgery, but patients are prone to drug resistance to Western medicine, and the recurrence rate of surgery is high, and dysmenorrhea cannot be cured.

[0004] Traditional Chinese medicine focuses on the cause of the disease, conducts syndrome differentiation and treatment, and applies different prescriptions according to the cause of the disease to fundamentally relieve the symptoms and reduce the incidence of dysmenorrhea. However, due to the inconvenience of boiling Chinese medicine, poor taste, and the need to take it for a long time, many women are unwilling to accept this treatment method. Summary of the invention

[0005] The purpose of the present invention is to provide a dysmenorrhea treatment instrument, which fundamentally solves the above problems and has the advantages of simple and compact structure, convenient use, and easy operation.

[0006] To achieve the above-mentioned purpose, the present invention provides the following technical solutions: the dysmenorrhea treatment device includes a shell, a vaporization component, and a hose assembly. The vaporization component includes a shell, a high-pressure cylinder assembly arranged in the shell, and a heating body. The technical key points are: the high-pressure cylinder assembly includes a first-level high-pressure chamber and a second-level high-pressure chamber arranged in upper and lower positions and connected through a first-level solenoid valve, the heating body is arranged at the bottom of the first-level high-pressure chamber, a buffer cylinder is provided on the side of the high-pressure cylinder assembly, and the buffer cylinder is connected to the second-level high-pressure chamber through a second-level solenoid valve; the buffer cylinder is connected to the hose assembly through a third-level solenoid valve.

[0007] Further, the hose assembly includes a hose connected to the buffer cylinder through a pipe joint and a three-stage solenoid valve, and a nozzle assembly provided at the end of the hose. The nozzle assembly includes a nozzle housing, an injection switch provided on the housing, a cold air bypass pipe, and a flow rate regulating assembly provided at the output end.

[0008] Further, the liquid medicine in the first-stage high-pressure chamber is prepared from the following raw materials:

[0009] 70-80 parts by weight of pilose antler;

[0010] 20-25 parts by weight of cyperus rotundus;

[0011] 2-5 parts by weight of mugwort oil;

[0012] and 5-10 parts by weight of peach kernels and 5-10 parts by weight of safflower;

[0013] or 5-10 parts by weight of codonopsis pilosula, 5-10 parts by weight of astragalus membranaceus, and 5-10 parts by weight of donkey-hide gelatin;

[0014] or 5-10 parts by weight of cinnamon and 5-10 parts by weight of evodia rutaecarpa.

[0015] The beneficial effects of the present invention: The high-pressure cylinder body assembly of the present invention adopts two-stage high-pressure cylinder bodies and one-stage buffer cylinder body, and cooperates with a three-stage solenoid valve for automatic pressure regulation, so as to continuously output the required steam. By setting the second-stage high-pressure chamber, the sudden change of air pressure caused by the direct connection of the first-stage high-pressure chamber to the atmosphere is avoided. By adopting the second-stage high-pressure chamber, when a small amount of high-pressure liquid medicine is connected to the buffer cylinder body, it is quickly decompressed and vaporized into liquid medicine steam, which cooperates with the piston of the buffer cylinder body, so as to ensure the continuous and constant-speed outflow of the liquid medicine steam, and cooperates with the adjustable-speed cold air bypass pipe on the nozzle assembly to output the treatment steam with ideal temperature and pressure.

[0016] In summary, the present invention can perform treatment and conditioning without contacting the skin, which is safer and has no side effects. It is combined with traditional Chinese medicine theory and selects genuine medicinal materials to ensure the curative effect. During the physiotherapy process, the medicine is always in a closed environment, avoiding the loss of effective ingredients, and the steam flow of the instrument can maximize the efficacy of the medicine by stimulating specific acupoints. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 is a schematic structural diagram of the present invention.

[0018] Figure 2 is a schematic diagram of the working principle of the flow rate regulating assembly of the present invention. DETAILED DESCRIPTION OF THE INVENTION

[0019] The following is combined with Figures 1 - 2, the content of the present invention will be described in detail through specific embodiments. The dysmenorrhea treatment instrument includes a housing 13, a vaporization assembly 1, a hose assembly 2, and a control system. The vaporization assembly 1 includes a housing 13, a high-pressure cylinder assembly 11 disposed within the housing 13, and a heating element 113. The high-pressure cylinder assembly 11 includes a first-stage high-pressure chamber 111 and a second-stage high-pressure chamber 112 which are vertically arranged and connected by a first-stage solenoid valve. The heating element 113 is disposed at the bottom of the first-stage high-pressure chamber 111. A buffer cylinder 12 is provided on the side of the high-pressure cylinder assembly 11. The buffer cylinder 12 is connected to the second-stage high-pressure chamber through a second-stage solenoid valve; the buffer cylinder 12 is connected to the hose assembly 2 through a third-stage solenoid valve 124. A drive gear 121, a rack 122 engaged with the drive gear 121, and a piston 123 disposed at the bottom of the rack 122 are provided in the buffer cylinder 12 through a drive motor; the drive gear 121 is a semi-tooth gear; the buffer cylinder 12 is connected to the hose assembly 2 through a third-stage solenoid valve 124. A heat insulation layer 131 is provided between the high-pressure cylinder assembly 11 and the housing 13, and the high-pressure cylinder assembly 11 is sealed by a sealing cover 132. A filter screen 111b is further provided in the first-stage high-pressure chamber 111. The filter screen 111b can hold the required medicinal materials, or directly place the pre-treated liquid medicine in the first-stage high-pressure chamber 111.

[0020] The control system includes a processor module, a signal input module, and a signal receiving module. Among them, the signal input module includes a pressure sensor I (not shown in the figure) disposed in the first-stage high-pressure chamber 111, a temperature sensor I, a pressure sensor II (not shown in the figure) disposed in the second-stage high-pressure chamber 112, a pressure sensor III (not shown in the figure) disposed in the buffer cylinder, a temperature sensor II disposed in the nozzle assembly 22, and a display screen 221 disposed on the outer wall of the nozzle assembly housing.

[0021] The receiving module includes a heating circuit, a first-stage solenoid valve 111a, a second-stage solenoid valve 112a, a third-stage solenoid valve 124, and a drive motor on the buffer cylinder.

[0022] The hose assembly 2 includes a hose 21 that is connected to the buffer cylinder through a pipe joint and a three-stage solenoid valve 124, and a nozzle assembly 22 provided at the end of the hose 21. The nozzle assembly 22 includes a nozzle housing 13, a spray switch 222 provided on the housing 13, a cold air bypass pipe 23, and a flow rate adjustment assembly 223 provided at the output end of the nozzle housing 13. Among them, the flow rate adjustment assembly 223 includes a plurality of blades 223a arranged circumferentially and an adjustment ring 223b. Each blade 223a is hinged to the adjustment ring 223b at equal angular intervals through a fixing post 223e, and the outer side of the blade 223a is limited in a limiting groove 223c inside the nozzle housing 13 through a limiting post 223d. During use, by rotating the knob on the nozzle housing 13, the adjustment ring 223b can be driven to rotate, thereby driving the blades 223a to swing between two positions of the limiting post 223d and the fixing post 223e, and further adjusting the size of the central exhaust hole.

[0023] By setting the one-way rotation of the output shaft of the drive motor (not shown in the figure), the rack 122 and the piston 123 can be driven by the drive gear 121 to reciprocate in the buffer cylinder body 12. Furthermore, the usable volume of the buffer cylinder body 12 (the lower area of the piston 123) can be adjusted. Assume that when the gear is in the Figure 1 position shown in the figure, the displacement of the piston in the vertical direction is 0, and the corresponding relationship between the gear angle and the rack displacement is shown in the following table.

[0024] Table 1 Corresponding relationship between gear rotation angle a and rack displacement d

[0025]

[0026] Note: When the rack is at the uppermost position, the displacement is Ymax, and the buffer cylinder body has the maximum volume Vmax;

[0027] When the rack is at the lowermost position, the displacement is -Ymax, and the buffer cylinder body has the minimum volume Vmin.

[0028] Taking the P1 threshold of 5 atm (boiling point 151.1 °C) as an example, the collaborative working process between each cavity and the solenoid valve will be described in detail. At the same time, considering factors such as safety, manufacturing cost, cylinder volume, and cylinder weight (the thicker the cylinder side wall, the greater the bearing capacity), the maximum pressure that the high-pressure cylinder assembly 11 can withstand is 10 atm to 15 atm. Of course, to extend the service life of the equipment, the threshold and the cylinder bearing capacity can also be increased accordingly.

[0029] For convenience of description, hereinafter, the pressure of the first - stage high - pressure chamber 111 is denoted as P1, the liquid temperature therein is denoted as T1, the gas temperature in the nozzle assembly is denoted as T2, the first - stage solenoid valve is denoted as v1, the pressure of the second - stage high - pressure chamber 112 is denoted as P2, the second - stage solenoid valve is denoted as v2, the pressure of the buffer cylinder is denoted as P3, the third - stage solenoid valve is denoted as v3, the heating circuit is denoted as H, and the atmospheric pressure is denoted as P0.

[0030] Table 2 Corresponding relationship between the signal input module and the signal receiving module in different states

[0031]

[0032] State I: When P1 < 5 atm, P2 << 5 atm, P3 = P0, and T1 < 150 °C, the heating circuit is connected and v1 - v3 are closed.

[0033] In addition, a protection circuit is provided on the heating element 113. No matter what state it is in, when T1 > the T1 threshold by a certain range, such as 20 °C - 50 °C higher than the T1 threshold temperature, it indicates that there is not much liquid left in the first - stage high - pressure chamber at this time. Then the heating circuit stops working, thus avoiding "dry burning" in the first - stage high - pressure chamber and shortening the life of the components.

[0034] State II: When P1 ≈ 5 atm, P2 < 5 atm, P3 = P0, and T1 ≈ 150 °C, the heating circuit is closed, v1 is opened, v2 - v3 are closed, and the liquid medicine in the first - stage high - pressure chamber enters the second - stage high - pressure chamber under the action of gravity.

[0035] State III: When P1 ≈ 5 atm, P2 ≈ 5 atm, P3 = P0, and T1 ≈ 150 °C, v1 - v3 are closed, and the second - stage high - pressure chamber 112 is filled with liquid medicine.

[0036] The volume of the second - stage high - pressure chamber 112 is much smaller than that of the first - stage high - pressure chamber 111. Since there is only a small amount of liquid, each time a part of the liquid medicine lost will not have a significant impact on P1. When the pressure in the second - stage high - pressure chamber 112 drops suddenly (connected to the buffer cylinder 12), all the liquid in the second - stage high - pressure chamber 112 quickly vaporizes without boiling violently. By setting the second - stage high - pressure chamber 112, it is also possible to avoid too large a change in air pressure caused by the direct connection of the first - stage high - pressure chamber 111 to the atmosphere, thereby improving safety.

[0037] State IV: v1 is closed, v2 is opened, v3 is closed, the liquid medicine in the second - stage high - pressure chamber quickly vaporizes and fills the buffer cylinder. At this time, P1 ≈ 5 atm, P0 < P2 = P3 < 5 atm.

[0038] State V: When the pressure P3 reaches the P3 threshold, v3 is opened, and at this time, physical therapy can be carried out by controlling the injection switch 222 and the flow - regulating component 223.

[0039] A temperature sensor (not shown in the figure) is provided inside the hose assembly 2. When the injection switch 222 of the hose assembly 2 is pressed, the three-way solenoid valve 124 opens, and steam enters the hose assembly 2 through the buffer cylinder body 12 and mixes with the bypass cooling gas of the hose assembly 2. The temperature sensor provided inside the hose assembly 2 detects the temperature of the gas inside the hose 21. When the temperature reaches the set value, the valve on the nozzle 22 can open to eject steam, and red and green indicator lights are provided. When T2 meets the set temperature, the indicator light is green, thus avoiding scalding. By setting the flow rate of the bypass cooling gas (since the P3 threshold is constant, the flow rate regulating device of the bypass is the temperature regulating device of the mixer), the temperature of the mixed steam finally discharged from the nozzle 22 can be set.

[0040] During the use process, when the pressure inside the hose assembly decreases, v2 and v3 are opened simultaneously, causing the liquid medicine in P2 to gradually vaporize. To prevent P2 and P3 from being too large, the volume of the buffer cylinder body can be adjusted by the drive motor inside the buffer cylinder body, thereby adjusting P2 and P3.

[0041] When P2 is less than the P2 threshold, v1 opens, v2 closes, and v3 opens, repeating state II and state III, and the liquid medicine fills the secondary high-pressure chamber again. To prevent the temporary pressure loss inside the hose caused by the closing of v2, the drive motor of the buffer cylinder body drives the piston to move to contract the volume of the buffer cylinder body to achieve a buffering effect. During the buffering process, the secondary high-pressure chamber is filled with liquid medicine again, and the pressure of P3 can be continuously maintained. Above, the liquid medicine in the primary high-pressure chamber can be safely and stably converted into a steam flow with a constant pressure and a constant temperature without interruption.

[0042] At the same time, to illustrate the safety of the high-pressure cylinder body of the present invention and the control relationship between the heat capacity of the liquid medicine and the pressure, the following table is given. The production standard of the liquefied gas tank complies with GB17267-1998 and can withstand a maximum of 2.1 Mpa (about 20 atm). The high-pressure cylinder body assembly of this embodiment not only has a much smaller volume than the liquefied gas tank, but also requires a relatively smaller bearing force, fully meeting the safety requirements in production and use. It can be seen that for every 1 atm increase in the P1 threshold, the heat carried by the liquid medicine of the same volume increases by about 10%.

[0043] Based on the above control method, the entire therapeutic instrument can be automatically controlled through embedded programming or a programmable processor (setting the threshold according to different situations). Through the processor module, the operating parameters of P1~P3, T1~T2, and the working state of H can be output to the display screen in real time, thus facilitating use.

[0044] Table 3 Boiling Point Comparison Table of Water under Different Pressure States

[0045]

[0046] For the treatment of dysmenorrhea, the solution in the primary high pressure chamber may be of the following composition:

[0047] Main ingredients:

[0048] 70-80 parts by weight of velvet antler

[0049] 20-25 parts by weight of Cyperus rotundus

[0050] 2-5 parts by weight of mugwort oil

[0051] Adjuvant:

[0052] Qi stagnation and blood stasis type: 5-10 weight parts of peach kernel and 5-10 weight parts of safflower;

[0053] For deficiency of Qi and blood, add 5-10 parts by weight of Codonopsis pilosula, 5-10 parts by weight of Astragalus membranaceus, and 5-10 parts by weight of donkey-hide gelatin;

[0054] For the type of internal excess of cold and dampness, 5-10 parts by weight of cinnamon bark and 5-10 parts by weight of Evodia rutaecarpa are added.

[0055] According to traditional Chinese medicine, the pathogenesis of dysmenorrhea is mainly due to the influence of pathogenic factors, which leads to Chongren and Baogong blood stasis or cold stagnation in the meridians, which makes the qi and blood flow poorly, and the menstrual blood flow in the uterus is hindered, resulting in "pain due to obstruction": or Chongren and Baogong are not nourished, and they are not nourished and painful. The disease is located in Chongren and Baogong, and the changes are in qi and blood, which manifests as pain. The reason why it occurs with the menstrual cycle is related to the changes in Chongren and Qi and blood during menstruation. Therefore, deer antler is selected to warm the kidney and nourish the kidney, replenish blood and nourish the marrow; Cyperus rotundus soothes the liver and relieves depression, regulates qi and relieves fullness, regulates menstruation and relieves pain; moxa oil warms the meridians and dredges the collaterals, removes blood stasis and relieves pain.

[0056] 1. Acupoints for Qi and blood stasis: Qihai, Baliao, Qimen, Ligou

[0057] 2. Acupoints for cold-dampness stagnation: Qihai, Baliao, Tianshu, Guanyuan

[0058] 3. Acupoints for deficiency-cold syndrome: Qihai, Baliao, Mingmen, Taixi

[0059] 4. Acupoints for Qi and blood deficiency: Qihai, Baliao, Zusanli, Pishu, Geshu

[0060] The dysmenorrhea therapeutic instrument selects pilose antler to warm the kidney and invigorate the kidney, benefit blood and supplement marrow; cyperus rotundus to soothe the liver and relieve depression, regulate qi and widen the middle, regulate menstruation and relieve pain; mugwort oil to warm the meridians and dredge collaterals, dispel stasis and relieve pain. According to the syndrome differentiation results of traditional Chinese medicine, herbs such as peach kernel, safflower, codonopsis pilosula, astragalus membranaceus, donkey-hide gelatin, cinnamon, evodia rutaecarpa, etc. are added, and appropriate acupoints are selected (the main acupoints include: qihai, baliao, qimen, ligou, tianshu, guanyuan, mingmen, taixi, zusanli, pishu, geshu, etc.). Place the treatment head of the dysmenorrhea therapeutic instrument about 1 cm above the selected acupoint, and instruct the patient to calm down and relax. Different time gears and front gears can be selected according to the degree of the disease. The more severe the disease, the larger the gear can be. It can be treated and conditioned without taking oral medicine and without contacting the skin, which can be safer and have no side effects, becoming a new method and choice for a wide range of female patients to solve the problem of dysmenorrhea.

[0061] Case 1:

[0062] Ms. Zhang, 16 years old, has had dysmenorrhea for 1 year. Her menstruation is regular (cycle 28 days, 3 - 5 days each time). One week before menstruation, there is soreness and discomfort in the lower abdomen, which feels cold when touched. The abdominal pain is obvious on the 1st and 2nd days of menstruation, and blood clots can be seen in the discharged blood, accompanied by general fatigue, sweating, and pale complexion. She has no other medical history in the past and has not taken any medicine to intervene in dysmenorrhea. On March 2, 2018, 5 days after the end of menstruation, she was enrolled in the observation and given treatment with the dysmenorrhea therapeutic instrument once a day for 1 hour each time. On April 1, 2018, on the 1st day of menstruation, there was no premenstrual syndrome, the lower abdomen was warm, the abdominal pain was significantly reduced, and there was no fatigue or sweating. She adhered to the intervention with the dysmenorrhea therapeutic instrument. On April 30, 2018, when menstruation came again, there was no discomfort before menstruation, no abdominal pain during menstruation, no blood clots in the menstrual blood, and no soreness and discomfort in the lower abdomen.

[0063] Case 2:

[0064] Ms. Li, 32 years old, has had a history of dysmenorrhea for 16 years. Her menstruation is irregular, with heavy menstrual flow and blood clots, and the severity of dysmenorrhea symptoms varies each time. Usually, the lower abdomen feels cold when touched, and she likes to drink cold drinks. When the dysmenorrhea attacks severely, she has to stay in bed and cannot work. She has no ovarian cysts, uterine fibroids, endometriosis in the past, no other medical history and no drug allergy history. On September 28, 2017, she was enrolled in the observation and given intervention with the dysmenorrhea therapeutic instrument once a day for 1 hour each time. On November 3, 2017, when menstruation came, there was soreness and swelling in the lower abdomen before menstruation, and the abdominal pain during menstruation was obvious but tolerable. The menstrual flow did not change, and small blood clots could still be seen. She adhered to the treatment with the dysmenorrhea therapeutic instrument unchanged. On December 21, 2017, when menstruation came again, there was no obvious discomfort before menstruation, the menstrual flow during menstruation decreased, there was no manifestation of unsmooth blood discharge, no blood clots, and there was a feeling of soreness and swelling in the lower abdomen, but the pain was not obvious. She continued to be given treatment with the dysmenorrhea therapeutic instrument once a day for 1 hour each time. On February 19, 2019, there was no discomfort during menstruation, the menstrual flow was normal, and there were no blood clots.

[0065] Case 3:

[0066] Ms. Yang, 12 years old, had abdominal pain and discomfort at the beginning of her menstruation, accompanied by sweating, pale face, cold lower abdomen and limbs. The menstrual flow was scanty, the menstrual blood was not smooth, and there were blood clots. Color Doppler ultrasound showed no other gynecological abnormalities, and there was no history of other diseases or allergies. She was enrolled in the group for observation one week after the end of her menstruation, and was given intervention with the dysmenorrhea treatment instrument once a day for 1 hour each time. On the 10th day of intervention with the dysmenorrhea treatment instrument, the temperature of the lower abdomen increased significantly, and it was warm to the touch, with no other discomfort symptoms. On the 20th day of intervention with the dysmenorrhea treatment instrument, the lower abdomen was warm to the touch, and she felt warm in the lower abdomen. On the 37th day of intervention with the dysmenorrhea treatment instrument, her menstruation came again, without abdominal pain and discomfort, the lower abdomen was warm, the menstrual blood flow was normal without blood clots, and there was no sweating or cold limbs.

[0067] From 2015 to 2019, a total of 308 women with dysmenorrhea were enrolled, and the total effective rate of the dysmenorrhea treatment device reached 99.8%, with an average application time of 87 days. The use of the dysmenorrhea treatment device provides a safer and more effective solution for patients with dysmenorrhea, and has become the preferred choice for more female patients with dysmenorrhea.

[0068] Description of reference numerals:

[0069] 1 Vaporization components

[0070] 11 High pressure cylinder assembly

[0071] 111 Level 1 high pressure chamber

[0072] 111a first stage solenoid valve

[0073] 111b filter

[0074] 112 Secondary high pressure chamber

[0075] 112a two-stage solenoid valve

[0076] 113 Heating element

[0077] 12 Buffer cylinder

[0078] 121 driving gear

[0079] 122 rack

[0080] 123 Piston

[0081] 124 three-stage solenoid valve

[0082] 13 Shell

[0083] 131 Insulation layer

[0084] 132 Sealing cover

[0085] 2 Hose Assemblies

[0086] 21 Hose

[0087] 22 Nozzle Assembly

[0088] 221 Display screen

[0089] 222 Jet switch

[0090] 223 Flow regulating component

[0091] 223a Vane

[0092] 223b Adjusting ring

[0093] 223c Limit groove

[0094] 223d Limit post

[0095] 223e Fixed post

[0096] 23 Cold air bypass pipe

Claims

1. A dysmenorrhea therapeutic apparatus, comprising a vaporization assembly (1), a hose assembly (2) and a control system. The vaporization assembly (1) includes a housing (13), a high-pressure cylinder assembly (11) disposed within the housing (13), and a heating element (113). It is characterized in that: The high-pressure cylinder assembly (11) includes a first-stage high-pressure chamber (111) and a second-stage high-pressure chamber (112) which are arranged vertically and communicated through a first-stage solenoid valve (111a). The heating element (113) is disposed at the bottom of the first-stage high-pressure chamber (111). A buffer cylinder (12) is provided on the side of the high-pressure cylinder assembly (11). The buffer cylinder (12) is communicated with the second-stage high-pressure chamber (112) through a second-stage solenoid valve (112a); the buffer cylinder (12) is communicated with the hose assembly (2) through a third-stage solenoid valve (124); the hose assembly (2) includes a hose (21) communicated with the buffer cylinder (12) through a pipe joint and a third-stage solenoid valve (124), and a nozzle assembly (22) disposed at the end of the hose (21). The nozzle assembly (22) includes a nozzle housing, a spray switch (222) disposed on the nozzle housing, a cold air bypass pipe (23), and a flow rate regulating assembly (223) disposed at the output end; The control system includes a processor module, a signal input module, and a signal receiving module. The receiving module includes a heating circuit, a first-stage solenoid valve (111a), a second-stage solenoid valve (112a), a third-stage solenoid valve (124), and a drive motor on the buffer cylinder (12); A drive gear (121), a rack (122) meshing with the drive gear (121), and a piston (123) disposed at the bottom of the rack (122) are provided in the buffer cylinder (12) through the drive motor; the signal input module includes a pressure sensor I disposed in the first-stage high-pressure chamber (111), a temperature sensor I, a pressure sensor II disposed in the second-stage high-pressure chamber (112), a pressure sensor III disposed in the buffer cylinder, and a temperature sensor II disposed in the nozzle assembly (22); Among them, the flow rate regulating assembly (223) includes a plurality of blades (223a) arranged circumferentially and an adjusting ring (223b). Each blade (223a) is hinged to the adjusting ring (223b) at equal angular intervals through a fixing column (223e). The outer side of the blade (223a) is limited within a limiting groove (223c) on the inner side of the nozzle housing through a limiting post (223d); during use, by rotating a knob on the nozzle housing, the adjusting ring (223b) can be driven to rotate, thereby driving the blade (223a) to swing at two points of the limiting post (223d) and the fixing column (223e), and further adjusting the size of the central exhaust hole; The pressure of the first-stage high-pressure chamber (111) is denoted as P1, the liquid temperature therein is denoted as T1, the gas temperature in the nozzle assembly (22) is denoted as T2, the pressure of the second-stage high-pressure chamber (112) is denoted as P2, the pressure of the buffer cylinder (12) is denoted as P3, and the atmospheric pressure is denoted as P0; State I: When P1 < 5 atm, P2 << 5 atm, P3 = P0, and T1 < 150 °C, the heating circuit is connected, and the first-stage solenoid valve (111a), the second-stage solenoid valve (112a), and the third-stage solenoid valve (124) are closed; State II: When P1 ≈ 5 atm, P2 < 5 atm, P3 = P0, and T1 ≈ 150 °C, the heating circuit is turned off, the first-stage solenoid valve (111a) is opened, the second-stage solenoid valve (112a) and the third-stage solenoid valve (124) are closed, and the liquid medicine in the first-stage high-pressure chamber (111) enters the second-stage high-pressure chamber (112) under the action of gravity; State III: When P1 ≈ 5 atm, P2 ≈ 5 atm, P3 = P0, and T1 ≈ 150 °C, the first-stage solenoid valve (111a), the second-stage solenoid valve (112a), and the third-stage solenoid valve (124) are closed, and the second-stage high-pressure chamber (112) is filled with liquid medicine; State IV: The first-stage solenoid valve (111a) is closed, the second-stage solenoid valve (112a) is opened, the third-stage solenoid valve (124) is closed, and the liquid medicine in the second-stage high-pressure chamber (112) quickly vaporizes and fills the buffer cylinder body (12). At this time, P1 ≈ 5 atm, P0 < P2 = P3 < 5 atm; State V: When the pressure of P3 reaches the P3 threshold value, the third-stage solenoid valve (124) is opened, and at this time, physical therapy can be carried out by controlling the injection switch (222) and the flow rate adjustment component (223); During the use process, when the pressure in the hose assembly decreases, the second-stage solenoid valve (112a) and the third-stage solenoid valve (124) are opened simultaneously, so that the liquid medicine in P2 gradually vaporizes. To avoid excessive P2 and P3, the volume of the buffer cylinder body (12) can be adjusted by the drive motor in the buffer cylinder body (12), thereby adjusting P2 and P3; When P2 is less than the P2 threshold value, the first-stage solenoid valve (111a) is opened, the second-stage solenoid valve (112a) is closed, the third-stage solenoid valve (124) is opened, and States II and III are repeated, and the second-stage high-pressure chamber (112) is filled with liquid medicine again; To avoid the temporary pressure loss in the hose caused by the closing of the second-stage solenoid valve (112a), the drive motor of the buffer cylinder body (12) drives the piston to move to contract the volume of the buffer cylinder body (12) to achieve a buffering effect. During the buffering process, the second-stage high-pressure chamber (112) is filled with liquid medicine again, and the pressure of P3 can be continuously maintained.

2. The dysmenorrhea therapeutic apparatus according to claim 1, characterized in that: A temperature sensor is arranged in the hose assembly (2). When the injection switch (222) of the hose assembly (2) is pressed, the third-stage solenoid valve (124) is opened, and the steam enters the hose assembly (2) through the buffer cylinder body (12) and is mixed with the bypass cooling gas in the hose assembly (2). The temperature sensor arranged in the hose assembly (2) detects the temperature of the gas in the hose (21). When the temperature reaches the set value, the valve on the nozzle assembly (22) can be opened to eject steam, and red and green indicator lights are set. When T2 meets the set temperature, the indicator light is green, so as to avoid scalding; The liquid medicine in the first-stage high-pressure chamber is prepared from the following raw materials: The liquid medicine in the first-stage high-pressure chamber (111) is prepared from the following raw materials: 70 - 80 parts by weight of pilose antler; 20 - 25 parts by weight of nutgrass galingale rhizome; 2 - 5 parts by weight of mugwort oil; 5 - 10 parts by weight of peach kernel and 5 - 10 parts by weight of safflower; or 5 - 10 parts by weight of codonopsis pilosula, 5 - 10 parts by weight of astragalus membranaceus and 5 - 10 parts by weight of donkey - hide gelatin; or 5 - 10 parts by weight of cinnamon and 5 - 10 parts by weight of evodia rutaecarpa.

Images